Evidence map›Paper›PMID 39189673›Full record

ArticleCell proliferation2025

The heterogeneity of cellular metabolism in the tumour microenvironment of hepatocellular carcinoma with portal vein tumour thrombus.

Xiu-Ping Zhang, Wen-Bo Zou, Zhen-Qi Li, Ze-Tao Yu, Shao-Bo Yu, Zhao-Yi Lin, Fei-Fan Wu, Peng-Jiong Liu, Ming-Gen Hu, Rong Liu and 1 more

Abstract read
In one paragraph

Article in Cell proliferation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiu-Ping ZhangFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Wen-Bo ZouFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Zhen-Qi LiFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Ze-Tao YuFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Shao-Bo YuDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
Zhao-Yi LinFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Fei-Fan WuFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Peng-Jiong LiuFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Ming-Gen HuFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Rong LiuFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.
Yu-Zhen GaoDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.ORCID https://orcid.org/0000-0001-7485-5237

Funding

Beijing Nova Program 20230484372Capital Health Research and Development of Special Fund 2024-4-5026National Key Research and Development Program of China 2022YFC2407402National Natural Science Foundation of China 32201232the Fundamental Research Funds for the Central Universities of HITYoung Elite Scientists Sponsorship Program by BAST BYESS2024001Young Elite Scientists Sponsorship Program by CAST 2023QNRC001
6 · The paper itself

Abstract

Given the growing interest in the metabolic heterogeneity of hepatocellular carcinoma (HCC) and portal vein tumour thrombus (PVTT). This study comprehensively analysed the metabolic heterogeneity of HCC, PVTT, and normal liver samples using multi-omics combinations. A single-cell RNA sequencing dataset encompassing six major cell types was obtained for integrated analysis. The optimal subtypes were identified using cluster stratification and validated using spatial transcriptomics and fluorescent multiplex immunohistochemistry. Then, a combined index based meta-cluster was calculated to verify its prognostic significance using multi-omics data from public cohorts. Our study first depicted the metabolic heterogeneity landscape of non-malignant cells in HCC and PVTT at multiomics levels. The optimal subtypes interpret the metabolic characteristics of PVTT formation and development. The combined index provided effective predictions of prognosis and immunotherapy responses. Patients with a higher combined index had a relatively poor prognosis (p <0.001). We also found metabolism of polyamines was a key metabolic pathway involved in conversion of metabolic heterogeneity in HCC and PVTT, and identified ODC1 was significantly higher expressed in PVTT compared to normal tissue (p =0.03). Our findings revealed both consistency and heterogeneity in the metabolism of non-malignant cells in HCC and PVTT. The risk stratification based on cancer-associated fibroblasts and myeloid cells conduce to predict prognosis and guide treatment. This offers new directions for understanding disease development and immunotherapy responses.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPortal VeinTumor MicroenvironmentHumansPrognosisVenous Thrombosis

Identifiers

PMID39189673
PMCPMC11693549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.